Transapical endovascular aortic repair to treat complex aortic pathologies.

Clinical condition, hostile anatomy, and previous heart/aortic surgery may preclude standard open surgery and standard endovascular interventions in patients with complex aortic pathologies. We report our initial experience using the transapical endovascular approach to treat a type IA endoleak after transfemoral endovascular graft repair for a contained rupture of a penetrating descending aortic ulcer; an ascending aortic anastomotic pseudoaneurysm after open surgical repair of an ascending aortic dissection; and a type A aortic dissection after minimally invasive mitral valve repair. There were no neurologic or cardiovascular complications, and the 30-day mortality was 0%.

Spontaneous coronary artery dissection.

Spontaneous coronary artery dissection (SCAD) is a rare and potentially deadly disease without a clear and universal treatment. Medical as well as mechanical interventions, including percutaneous and coronary bypass surgery, have been used. We present two dissimilar cases of SCAD that required markedly different treatments reflecting the variety in clinical presentation and outcome. A brief review of the literature is included.

Treatment of mediastinitis with wound-vacuum without muscle flaps.

Wound vacuum may represent a new solution to the treatment of patients with mediastinitis. We herein present case reports of two patients with very serious deep wound infections of the sternum (mediastinitis) treated with wound vacuum without muscle flaps. The implications of this new modality of treatment are discussed.

Proteasome peptidase activities parallel histomorphological and functional consequences of ischemia-reperfusion injury in the lung.

Several lines of evidence suggest that the proteasome contributes to ischemia-reperfusion injury (I-RI) of organs. Although I-RI contributes to multiple disease processes in the lung, the regulation of proteasome activities during pulmonary I-RI is unknown. Thus, the authors performed a pilot study to define time-related changes of lung proteasome peptidase activities and to evaluate if possible alterations correspond to morphological and functional consequences of I-RI using a rat model. Animals underwent 120 minutes of unilateral lung ischemia. Ischemic and contralateral lungs were harvested at multiple time points for up to 168 hours of reperfusion (I-R30 min-168 h). Chymotryptic-like (CT-L) and tryptic-like (T-L) proteasome peptidase activities were measured in lung extracts. An early I-R-associated inactivation of proteasome activities paralleled impairment of oxygenation, edema formation, and degree of histopathology, and resolved with restoration of function within 24 to 72 hours. Although functional and histomorphological baseline conditions were still not fully achieved at I-R168h, proteasome activities increased continuously 1.4-fold (CT-L) and 5.7-fold (T-L) until I-R168h. Apparent K(M) values for the CT-L/T-L substrates were not influenced by I-R. This pilot study establishes an initial link between proteasome activities and physiological relevant consequences of lung I-RI, and further points towards a possible role of the proteasome during the postischemic tissue repair process.

Right atrial and pulmonary tumor embolism from renal rhabdomyosarcoma.

A 66-year-old male presented with rhabdomyosarcoma of the right kidney with inferior vena cava tumor thrombus and with tumor emboli to right pulmonary artery and two large fragments of tumor thrombus free floating in the right atrium. The patient underwent right radical nephrectomy and thrombectomy of the right atrium and pulmonary artery. He was discharged on postoperative day 13. To our knowledge this is the first case of large tumor embolism to the right atrium and pulmonary artery from renal rhabdomyosarcoma reported in the literature.

Ubiquitin enhances the Th2 cytokine response and attenuates ischemia-reperfusion injury in the lung.

OBJECTIVE: To determine whether ubiquitin treatment modulates the lung cytokine response and attenuates lung ischemia-reperfusion injury. DESIGN AND SETTING: Randomized and blinded treatment of unilateral lung ischemia-reperfusion injury in a research laboratory. SUBJECTS: Twenty anesthetized and mechanically ventilated Brown Norway rats. INTERVENTIONS: Unilateral clamping of the left lung for 90 mins followed by 60 mins of reperfusion. Intravenous administration of 1.5 mg/kg of ubiquitin (n = 10) or albumin (n = 10) 5 mins before reperfusion. MEASUREMENTS AND MAIN RESULTS: Blood pressure was measured by the tail-cuff method. Oxygenation via the ischemic lung was assessed by PaO2 measurements after right lung exclusion. Wet-to-dry weight ratios of the ischemic lungs were determined gravimetrically. Tissue homogenates (n = 5/group) were prepared from ischemic lungs at the end of reperfusion and assayed for malondialdehyde in combination with 4-hydroxyalkenals to assess lipid peroxidation, and for a panel of 22 cytokines/chemokines using a multiplex assay. Ubiquitin serum levels were determined by enzyme-linked immunosorbent assay.All animals were hemodynamically stable during the experimental procedure. Ubiquitin serum levels (mean +/- SD) were 650 +/- 40 ng/mL in controls and 1206 +/- 181 ng/mL in the ubiquitin treatment group at the end of the experiment. PaO2 after right lung exclusion was 45 (32-72) mm Hg with albumin and 61 (range, 36-132) mm Hg with ubiquitin (p = .0185). Wet-to-dry weight ratios of the injured lungs were 8.7 (range, 5.5-19.1) and 7.8 (range, 5.7-8.3) in the albumin and ubiquitin groups, respectively (p = .035). Malondialdehyde/4-hydroxyalkenals concentrations (mean +/- SD, nmol/mg protein) were 2.5 +/- 0.4 with ubiquitin and 3.0 +/- 0.3 with albumin (p > .05). Concentrations of the interleukins 4, 10, and 13 were significantly increased in lung homogenates after ubiquitin treatment (p < .05). CONCLUSION: Ubiquitin treatment enhances the Th2 cytokine response in postischemic lungs during reperfusion, reduces lung edema formation, and improves pulmonary function during lung ischemia-reperfusion injury. This study further defines ubiquitin's anti-inflammatory properties, and suggests that it could be used therapeutically to improve function of postischemic lungs.

[Lung transplantation. State of the art]. / Estado actual del trasplante pulmonar.

Lung transplantation is currently considered an established treatment for some advanced lung diseases. The beginning of experimental lung transplantation dates back to the 1940's when the Soviet Vladimir P. Demikhov performed the first lung transplants in animals. Two decades later, James Hardy performed the first lung transplant in humans. Unfortunately, the beginning of clinical lung transplantation was hampered by technical complications and the excessive toxicity of immunosuppressive drugs. Improvement in the surgical technique along with the development of more effective and less toxic immunosuppressive drugs has led to a better outcome in lunt transplant recipients. Donor selection and management before organ procurement play a key role in the receptor's outcome. Due to the shortage of donors, some institutions are using more liberal selection criteria, reporting satisfactory outcomes. The approach of the lung and heart-lung transplant patient is multidisciplinary and includes the cardiothoracic transplant surgeon, pulmonologist, anesthesiologist, and intensivist, among others. Herein, we review some relevant historical aspects and recent advances in the management of lung transplant recipients, including indications and contraindications, evaluation of donors and recipients, surgical techniques and peripost-operative care.

Estado actual del trasplante pulmonar / Lung transplantation: state of the art

Actualmente el trasplante pulmonar es considerado como tratamiento definitivo para algunas enfermedades pulmonares avanzadas. Los primeros trasplantes pulmonares experimentales en animales fueron realizados en los años 1940’s por el soviético Vladimir P. Demikhov. Sin embargo, pasaron aproximadamente dos décadas antes de que se realizara el primer trasplante pulmonar en humanos por el doctor James Hardy. Desafortunadamente los inicios clínicos del trasplante pulmonar no fueron muy exitosos debido a complicaciones quirúrgicas y efectos secundarios de los fármacos inmunosupresores. Gracias al mejoramiento de la técnica quirúrgica y al desarrollo de fármacos inmunosupresores más efectivos y menos tóxicos, la morbimortalidad ha disminuido significativamente. La selección y el cuidado del donador antes de la procuración de los órganos juegan un papel primordial en los resultados en el receptor. Debido a la escasez de donadores, algunas instituciones están utilizando criterios de selección más liberales con resultados satisfactorios. El manejo del paciente con trasplante pulmonar o del bloque cardiopulmonar requiere de un enfoque multidisciplinario que incluye al cirujano de trasplantes cardiotorácicos, al neumólogo, al anestesiólogo y al intensivista entre otros. En este artículo revisamos aspectos históricos y avances recientes en el manejo de estos pacientes incluyendo indicaciones y contraindicaciones, evaluación y cuidado del donador y del receptor, técnica quirúrgica y manejo peri- y posoperatorio.

Lung transplantation is currently considered an established treatment for some advanced lung diseases. The beginning of experimental lung transplantation dates back to the 1940's when the Soviet Vladimir P. Demikhov performed the first lung transplants in animals. Two decades later, James Hardy performed the first lung transplant in humans. Unfortunately, the beginning of clinical lung transplantation was hampered by technical complications and the excessive toxicity of immunosuppressive drugs. Improvement in the surgical technique along with the development of more effective and less toxic immunosuppressive drugs has led to a better outcome in lunt transplant recipients. Donor selection and management before organ procurement play a key role in the receptor's outcome. Due to the shortage of donors, some institutions are using more liberal selection criteria, reporting satisfactory outcomes. The approach of the lung and heart-lung transplant patient is multidisciplinary and includes the cardiothoracic transplant surgeon, pulmonologist, anesthesiologist, and intensivist, among others. Herein, we review some relevant historical aspects and recent advances in the management of lung transplant recipients, including indications and contraindications, evaluation of donors and recipients, surgical techniques and peripost-operative care.

Omental torsion mimicking acute appendicitis: a case report.

Primary omental torsion is an uncommon cause of an acute abdomen that can mimic acute appendicitis. Herein we report a case of suspected acute appendicitis that proved to be a distal segment of infarcted omentum secondary to primary torsion.

Adjuvant hyperbaric oxygen therapy in the management of crush injury and traumatic ischemia: an evidence-based approach.

Hyperbaric oxygen therapy (HBO) has been recommended as an adjunct treatment in acute traumatic ischemia and crush injury. Several animal models have shown better outcomes when HBO is used in crush injury and compartment syndrome. Animal and in vitro models have suggested that these beneficial effects may be mediated by attenuation of ischemia-reperfusion injury. We did a systematic review of the literature using the Eastern Association for the Surgery of Trauma (EAST) recommendations for evidence-based reviews. An electronic search using Medline, OVID technologies, and the Cochrane database was performed. Only clinical papers published between 1966 and December 2003 with at least five patients that included enough information to evaluate were selected. A group of trauma experts reviewed the selected articles and scored them applying the instrument developed by the EAST practice management guidelines committee. Nine documents fulfilled the inclusion criteria for a total of approximately 150 patients. Most documents were retrospective, uncontrolled, and case series lacking a standardized methodology (class III). There was one prospective controlled randomized trial with some limitations on its design. We determined that eight of nine studies showed a beneficial effect from HBO with only one major complication. We concluded that adjunctive HBO is not likely to be harmful and could be beneficial if administered early. Well designed clinical studies are warranted.

Cadaveric kidney transplant complicated by rupture of native kidney angiomyolipoma: a case report and review of the literature.

Kidneys with angiomyolipomas have been used for transplantation, but we are unaware of postoperative hemorrhage from a native kidney angiomyolipoma. A 49-year-old male who underwent a cadaveric renal transplant complicated by postoperative hemorrhage from a native kidney angiomyolipoma is presented. Evaluation and current management strategies are discussed.

[Treatment of mucormycosis with adjunctive hyperbaric oxygen: five cases treated at the same institution and review of the literature]. / Tratamiento adjunto con oxigenación hiperbárica en mucormicosis. Presentación de cinco casos tratados en la misma institución y revisión de la literatura.

INTRODUCTION: Mucormycosis is an invasive fungal infection that affects decompensated diabetics, immunosupressed patients and occasionally healthy individuals. Despite advances in anti-fungal therapy and surgical techniques, the morbidity and mortality remain high. Adjuvant hyperbaric oxygen therapy (HBO) has been proposed based on pathophysiology and several favorable clinical reports. MATERIAL AND METHODS: A chart review of mucormycosis patients referred to the HBO service was performed. Also an electronic search in Medline of relevant literature was undertaken. RESULTS: Five mucormycosis patients referred for HBO had complete charts available. Four had craniofacial involvement and one had left upper extremity involvement. The predisposing diseases were leukemia (n = 3), diabetes mellitus plus sarcoidosis (n = 1), and trauma (n = 1). All patients were managed with amphotericin B, surgical debridement and HBO. Survival was 60% (3/5) three months after the diagnosis was established. The literature was scarce but favors HBO. CONCLUSION: Considering the pathophysiology of mucormycosis adjuvant HBO therapy seems reasonable. However, the clinical experience is still too limited to make HBO part of the standard of care. Prospective, randomized, controlled trials will help to define the role of HBO in this devastating infection.

Tratamiento adjunto con oxigenación hiperbárica en mucormicosis. Presentación de cinco casos tratados en la misma Institución y revisión de la literatura / Treatment of mucormycosis with adjunctive hyperbaric oxygen: five cases treated in the some institution and review of the literature

Introduction. Mucormycosis is an invasive fungal infection that affects decompensated diabetics, immunosupressed patients and occasionally healthy individuals. Despite advances in anti-fungal therapy and surgical techniques, the morbidity and mortality remain high. Adjuvant hyperbaric oxygen therapy (HBO) has been proposed based on pathophysiology and several favorable clinical reports. Material and methods. A chart review of mucormycosis patients referred to the HBO service was performed. Also an electronic search in Medline of relevant literature was undertaken. Results. Five mucormycosis patients referred for HBO had complete charts available. Four had craniofacial involvement and one had left upper extremity involvement. The predisposing diseases were leukemia (n = 3), diabetes mellitus plus sarcoidosis (n = 1), and trauma (n = 1). All patients were managed with amphotericin B, surgical debridement and HBO. Survival was 60% (3/5) three months after the diagnosis was established. The literature was scarce but favors HBO. Conclusion. Considering the pathophysiology of mucormycosis adjuvant HBO therapy seems reasonable. However, the clinical experience is still too limited to make HBO part of the standard of care. Prospective, randomized, controlled trials will help to define the role of HBO in this devastating infection.

Introducción. La mucormicosis es una infección micótica invasiva que se presenta principalmente en pacientes diabéticos descompensados, pacientes con afección del sistema inmune, e incluso en individuos previamente sanos. A pesar de los avances en medicamentos y técnicas quirúrgicas la morbimortalidad es todavía muy elevada. La terapia adjunta con oxígeno hiperbárico (OHB) ha sido sugerida con base en fundamentos fisiopatológicos y algunos reportes clínicos favorables. Material y métodos. Revisión de expedientes de pacientes referidos al Servicio de OHB con diagnóstico de infecciones micóticas invasivas. Búsqueda electrónica en Medline de literatura pertinente. Resultados. Cinco pacientes con diagnóstico clínico e histopatológico de mucormicosis con expediente completo fueron referidos a OHB para terapia adjunta. Cuatro presentaron afección craneofacial y uno afección de la extremidad superior izquierda. La enfermedad predisponente fue leucemia (n = 3), sarcoidosis y diabetes mellitus (n = 1) y trauma (n = 1). Todos fueron manejados con anfotericina B, debridación quirúrgica y OHB. La sobrevida fue 60% (3/5) tres meses después del diagnóstico. La literatura al respecto es escasa, pero favorece al OHB. Conclusión. Con base en la fisiopatología de la mucormicosis la terapia adjunta con OHB parece lógica. No obstante, la información clínica es todavía muy limitada para recomendar OHB rutinariamente en estos pacientes. Estudios prospectivos, aleatorios, controlados ayudarán a definir el papel del OHB en el manejo de esta devastadora infección.

Invasive aspergillosis treated with adjunctive hyperbaric oxygenation: a retrospective clinical series at a single institution.

BACKGROUND: Invasive aspergillosis is the leading cause of early death in many transplant centers and has a major impact on the management of hematologic malignancies. The mortality rate with current therapy (amphotericin B and surgery) has remained unacceptably high. In vitro data along with a few case reports have suggested a potential benefit of hyperbaric oxygen (HBO). METHODS: We retrospectively studied all patients referred to our service when histologic specimens suggested invasive aspergillosis. Our main assessment of outcome was survival 3 months after initiation of HBO. RESULTS: Ten patients were included. All received adjunctive HBO along with the standard of care. Rhinosinusinal infection was the primary presentation. The most common underlying conditions were hematologic malignancies. Six patients were free of signs of infection 3 months after the first HBO treatment. CONCLUSIONS: Adjunctive HBO appears to be a valuable tool in this devastating condition. Further studies are warranted to clarify its role.

Terapia con oxigenación hiperbárica, concepto básico / Therapy with hyperbaric oxygenation. Basic concepts

La Oxigenación Hiperbárica (OHB) es definida como la terapia en que se respira oxigeno al 100 por ciento en un ambiente presurizado a por lo menos 1.4 atmósferas absolutas. Sus inicios se remontan al S.XV cuando se utilizó para tratar enfermedades respiratorias. Durante algún tiempo sus aplicaciones carecieron de bases científicas hasta mediados de este siglo en que se realizan trabajos apegados a la metodología actual demostrando su aplicación en patologías que tienen de base tienen hipoxia/isquemia.Esta modalidad de tratamiento se fundamenta principalmente en tres leyes de los gases: Ley de Henry, Ley de Dalton y Ley de Boyle. Los beneficios en el organismo, como promoción del proceso de cicatrización, aumento de la capacidad bactericida del neutrófilo, efecto tóxico directo sobre algunos microorganismos, vasoconstricción arteriolar con la consecuente reducción del edema y disminución de la lesión por isquemia reperfusión, entre otros, son como resultado de la presión ambiental aumentada y la hiperoxigenación de los tejidos en el organismo. Actualmente existen 13 condiciones aceptadas por la UHMS para ser tratadas con OHB y varias mas se encuentran en investigación. Siguiendo los protocolos de tratamiento indicados por la UHMS, las complicaciones y/o efectos adversos son escasos.

Terapia con oxígeno hiperbárico: revisión / Hyperbaric oxygen therapy: review

Se presenta una revisión de los beneficios y riesgos de la terapia por oxigenación hiperbárica (TOH), así como sus indicaciones terapéuticas, poniendo especial énfasis en el tratamiento de pacientes pediátricos. Con la aplicación de la TOH se logra una reducción de 25 a 30 por ciento en la morbi-mortalidad, la estancia hospitalaria, la necesidad de cirugía y sus complicaciones, el número de amputaciones y, por consiguiente, el costo total de la atención médica